Tweets
Meta-analysis of 3 RCTs (n=1990) shows IL-17i offers comparable joint response but superior skin clearance vs adalimumab in biologic-naive PsA. IL-17i also had fewer discontinuations due to adverse events. Supports sequencing of biologics through different mechanisms of action in https://t.co/SJgFUMxWVb
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
2 months 2 weeks ago
IgG4-RD continues to present in new and unusual ways
Hasbani et al. report 9 IgG4-RD patients with coronary artery involvement
RCA and LAD most affected
Seen on CTA
Majority received RTX
7/9 pt at least partially improved imaging on f/u
@RheumNow #ACR25 Abst 2531 https://t.co/Na0gdq3dgb
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
2 months 2 weeks ago
A new genetic score for ILD prediction! 🫁
Developed in the Veterans RA cohort and Validation in a Swedish cohort
Model using classic RA-ILD risk factors and a cocktail of genetic risk
A cut off of 0.05 in this cohort would exclude 36% from HRCT or PFTs
Good performance https://t.co/6UsoSQAtyK
Links:
Aurelie Najm @AurelieRheumo ( View Tweet )
2 months 2 weeks ago
RESET-RA, RCT of vagus nerve stim (device that zaps pts in neck)
Marginal improvements in ACR20 at wk 12; trend in to improvement in unblinded part of study fwiw
Have never seen result that is more likely to be driven by plbo effect & unblinding 🤪
@RheumNow #ACR25 Abstr#2278 https://t.co/BlR570nv7k
Links:
Mike Putman @EBRheum ( View Tweet )
2 months 2 weeks ago
Hindosh et al. Semaglutide associated with reduced synovitis, joint pain and swelling, in RA. @RheumNow #ACR25 Abstr#2286 https://t.co/6Xs4um5l32
Richard Conway @RichardPAConway ( View Tweet )
2 months 2 weeks ago
MSK side effects of CAR-T, based on FAERS pharmacovigilance data (also see @DrGomezPuerta in @seminarthrheum https://t.co/LnwjU5aebs) #ACR25 ABST1731 @RheumNow https://t.co/kREEy3HLE9
Links:
David Liew @drdavidliew ( View Tweet )
2 months 2 weeks ago
Late Breaker: Observational study of MEPO in EGPA
375 pts receiving MEPO had less ARF/CKD than 727 pts receiving standard of care
Smallish event #'s & lots of p values... also, what about the vasculitis?!?
#ACR25 @RheumNow AbstLB16 https://t.co/XwqNthfwPF
Links:
Mike Putman @EBRheum ( View Tweet )
2 months 2 weeks ago
Bremer et al. Earlier initiation of biosimilar adalimumab (vs csDMARDs) may result in cost-savings. Reduced cost of tests, consultations, and hospitalisations. @RheumNow #ACR25 Abstr#2271 https://t.co/lHaSiX3WLd
Richard Conway @RichardPAConway ( View Tweet )
2 months 2 weeks ago
Semaglutide isn’t just for weight loss?
In RA, users had 20–40% lower risk of synovitis, stiffness & swelling up to 1 year vs matched controls.
GLP-1 agonists may offer anti-inflammatory benefit beyond metabolism.
@RheumNow #ACR25 Abstract#2286
Jiha Lee @JihaRheum ( View Tweet )
2 months 2 weeks ago
PLEX continues to be OUT for DAH in AAV
Retrospective review of ~1.4k AAV-DAH pt
375 who received PLEX compared to those who did not
PLEX tx patients:
- higher odds of death
- higher sepsis
- increased LOS
- increased hospitalization cost
@RheumNow #ACR25 Abst 2517
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
2 months 2 weeks ago
Mateo Faxas et al. TriNetX study, propensity score matched. 3000 patients. Arrythmia risk is higher with IL-6i vs TNFi in diabetic RA patients. V Tachy (HR 1.4), PPM need (HR 1.4) significantly higher. AF, SVT, VF all numerically increased. @RheumNow #ACR25 Abstr#2283 https://t.co/U2Tk38Mobg
Richard Conway @RichardPAConway ( View Tweet )
2 months 2 weeks ago
Heydari-Kamjani et al. TriNetX study. 28973 PsA patients. IL-17i and IL-23i lower rates stroke, MI, DVT/PE than TNFi. IL-12/23i higher rate of stroke vs TNFi. @RheumNow #ACR25 Abstr#2363 https://t.co/fNHaxyYPCP
Richard Conway @RichardPAConway ( View Tweet )
2 months 2 weeks ago
